- Adaptive Biotechnologies' clonoSEQ MRD test is highlighted in 30 presentations at ASCO and EHA 2025.
- Key presentations include data from significant trials like MIDAS, ADVANCE, and VENETOSTOP.
- The clonoSEQ test is used to guide therapy in multiple myeloma and chronic lymphocytic leukemia.
Adaptive Biotechnologies (ADPT, Financial), a leader in harnessing the genetics of the immune system for disease diagnosis and treatment, announced its clonoSEQ measurable residual disease (MRD) test will be featured in 30 scientific presentations at the ASCO and EHA 2025 conferences. Notably, 14 of these will be oral presentations, emphasizing the test's clinical utility across various blood cancers.
The clonoSEQ test's role in managing multiple myeloma is underscored by several notable studies. The MIDAS Phase 3 trial, involving 718 patients, demonstrated how MRD status could effectively guide post-induction therapy in newly diagnosed multiple myeloma patients. Furthermore, the ADVANCE Phase 2 trial with 306 patients reinforced clonoSEQ's impact on treatment assessment. Additionally, the VENETOSTOP study in chronic lymphocytic leukemia (CLL) highlighted the potential for clonoSEQ to optimize and possibly shorten venetoclax-based therapy duration.
clonoSEQ's efficacy was also evaluated in multiple myeloma through trials examining quadruplet regimens, such as the IsKia, PERSEUS, and DREAMM-8 studies. These trials showed superior outcomes, including higher MRD negativity rates, when combining agents like isatuximab, daratumumab, and belantamab mafodotin.
This extensive scientific presence at ASCO and EHA positions Adaptive Biotechnologies favorably in the market, enhancing the clonoSEQ test's adoption in clinical care and drug development across lymphoid cancers.
